TY - JOUR
T1 - 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report
AU - 100,000 Genomes Project Pilot Investigators
AU - Smedley, Damian
AU - Martin, Antonio
AU - Thomas, Ellen A
AU - McDonagh, Ellen M
AU - Cipriani, Valentina
AU - Ellingford, Jamie M
AU - Arno, Gavin
AU - Tucci, Arianna
AU - Vandrovcova, Jana
AU - Chan, Georgia
AU - Williams, Hywel J
AU - Ratnaike, Thiloka
AU - Wei, Wei
AU - Stirrups, Kathleen
AU - Ibanez, Kristina
AU - Moutsianas, Loukas
AU - Wielscher, Matthias
AU - Need, Anna
AU - Barnes, Michael R
AU - Vestito, Letizia
AU - Buchanan, James
AU - Wordsworth, Sarah
AU - Ashford, Sofie
AU - Rehmström, Karola
AU - Li, Emily
AU - Fuller, Gavin
AU - Spasic-Boskovic, Olivera
AU - Halsall, Sally
AU - Floto, R Andres
AU - Poole, Kenneth
AU - Wagner, Annette
AU - Mehta, Sarju G
AU - Gurnell, Mark
AU - Burrows, Nigel
AU - James, Roger
AU - Penkett, Christopher
AU - Dewhurst, Eleanor
AU - Gräf, Stefan
AU - Mapeta, Rutendo
AU - Kasanicki, Mary
AU - Savage, Helen
AU - Devereau, Andrew
AU - Wallis, Colin
AU - Banka, Siddharth
AU - Clayton-Smith, Jill
AU - Douzgou, Sofia
AU - Hall, Georgina
AU - O'Keefe, Raymond T
AU - Black, Graeme
AU - Newman, William
N1 - Copyright © 2021 Massachusetts Medical Society.
PY - 2021/11/11
Y1 - 2021/11/11
N2 - BACKGROUND The U.K. 100,000 Genomes Project is in the process of investigating the role of genome sequencing in patients with undiagnosed rare diseases after usual care and the alignment of this research with health care implementation in the U.K. National Health Service. Other parts of this project focus on patients with cancer and infection. METHODS We conducted a pilot study involving 4660 participants from 2183 families, among whom 161 disorders covering a broad spectrum of rare diseases were present. We collected data on clinical features with the use of Human Phenotype Ontology terms, undertook genome sequencing, applied automated variant prioritization on the basis of applied virtual gene panels and phenotypes, and identified novel pathogenic variants through research analysis. RESULTS Diagnostic yields varied among family structures and were highest in family trios (both parents and a proband) and families with larger pedigrees. Diagnostic yields were much higher for disorders likely to have a monogenic cause (35%) than for disorders likely to have a complex cause (11%). Diagnostic yields for intellectual disability, hearing disorders, and vision disorders ranged from 40 to 55%. We made genetic diagnoses in 25% of the probands. A total of 14% of the diagnoses were made by means of the combination of research and automated approaches, which was critical for cases in which we found etiologic noncoding, structural, and mitochondrial genome variants and coding variants poorly covered by exome sequencing. Cohortwide burden testing across 57,000 genomes enabled the discovery of three new disease genes and 19 new associations. Of the genetic diagnoses that we made, 25% had immediate ramifications for clinical decision making for the patients or their relatives. CONCLUSIONS Our pilot study of genome sequencing in a national health care system showed an increase in diagnostic yield across a range of rare diseases.
AB - BACKGROUND The U.K. 100,000 Genomes Project is in the process of investigating the role of genome sequencing in patients with undiagnosed rare diseases after usual care and the alignment of this research with health care implementation in the U.K. National Health Service. Other parts of this project focus on patients with cancer and infection. METHODS We conducted a pilot study involving 4660 participants from 2183 families, among whom 161 disorders covering a broad spectrum of rare diseases were present. We collected data on clinical features with the use of Human Phenotype Ontology terms, undertook genome sequencing, applied automated variant prioritization on the basis of applied virtual gene panels and phenotypes, and identified novel pathogenic variants through research analysis. RESULTS Diagnostic yields varied among family structures and were highest in family trios (both parents and a proband) and families with larger pedigrees. Diagnostic yields were much higher for disorders likely to have a monogenic cause (35%) than for disorders likely to have a complex cause (11%). Diagnostic yields for intellectual disability, hearing disorders, and vision disorders ranged from 40 to 55%. We made genetic diagnoses in 25% of the probands. A total of 14% of the diagnoses were made by means of the combination of research and automated approaches, which was critical for cases in which we found etiologic noncoding, structural, and mitochondrial genome variants and coding variants poorly covered by exome sequencing. Cohortwide burden testing across 57,000 genomes enabled the discovery of three new disease genes and 19 new associations. Of the genetic diagnoses that we made, 25% had immediate ramifications for clinical decision making for the patients or their relatives. CONCLUSIONS Our pilot study of genome sequencing in a national health care system showed an increase in diagnostic yield across a range of rare diseases.
U2 - 10.1056/NEJMoa2035790
DO - 10.1056/NEJMoa2035790
M3 - Article
C2 - 34758253
SN - 1533-4406
VL - 385
SP - 1868
EP - 1880
JO - The New England Journal of Medicine
JF - The New England Journal of Medicine
IS - 20
ER -